ormulation of precise control strategies tailored for ADCs, Peptides and other New Modalities, supporting regulatory compliance and commercial success. As Chair of the Impurity Advisory Group at AstraZeneca, Dr Osama Chahrour leads initiatives to assess, control, and mitigate impurities in complex manufacturing, with a particular focus on application to real life scenarios. Through external advocacy at EFPIA and the IQ Consortium, he has championed industry-wide best practices and collaborative standards for complex biologics. With a track record of impactful publications, he has advanced methodologies for optimizing peptides manufacturing and ensuring robust quality control throughout product lifecycle.

Experience organising scientific training courses and conferences for CMC leaders worldwide

25:T5f1,

Our expertise spans process characterization, analytical technology, and the formulation of precise control strategies tailored for ADCs, Peptides and other New Modalities, supporting regulatory compliance and commercial success. As Chair of the Impurity Advisory Group at AstraZeneca, Dr Osama Chahrour leads initiatives to assess, control, and mitigate impurities in complex manufacturing, with a particular focus on application to real life scenarios. Through external advocacy at EFPIA and the IQ Consortium, he has championed industry-wide best practices and collaborative standards for compl

ADC Therapeutics CMC: Impurities Management and Control Strategy